SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders
FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer.
- FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer.
- On February 11, 2020, FibroGen announced that the FDA had completed its filing review of its NDA for roxadustat.
- FibroGen acknowledged that it could no longer conclude that roxadustat reduces the risk of cardiovascular events or hospitalization when compared to a currently approved anemia injection used as a control.
- Shareholders pay no fees or expenses.\nContact us to learn more:\n'